BACKGROUND: Schizophrenia is a heritable disorder associated with disrupted neural transmission and dysfunction of brain systems involved in higher cognition. The gene encoding dystrobrevin-binding-protein-1 (dysbindin) is a putative candidate gene associated with cognitive impairments, including memory deficits, in both schizophrenia patients and unaffected individuals. The underlying mechanism is thought to be based in changes in glutamatergic and dopaminergic function within the corticostriatal networks known to be critical for schizophrenia. This hypothesis derives support from studies of mice with a null mutation in the dysbindin gene that exhibit memory dysfunction and excitatory neurotransmission abnormalities in prefrontal and hippocampal networks. At a cellular level, dysbindin is thought to mediate presynaptic glutamatergic transmission. METHODS: We investigated the relationship between glutamate receptor dynamics and memory performance in dysbindin mutant mice. We assessed N-methyl-D-aspartate (NMDA) and α-amino-3-hydroxy-5-methylisoxazole-4-propionic acid receptor function in prefrontal cortex pyramidal neurons in vitro with whole-cell recordings, molecular quantitative analyses (reverse transcription-polymerase chain reaction) of the mandatory NMDA receptor subunit NR1, and cognitive function with a spatial working memory task. RESULTS: Decreases in dysbindin are associated with specific decreases in NMDA-evoked currents in prefrontal pyramidal neurons, as well as decreases in NR1 expression. Furthermore, the degree of NR1 expression correlates with spatial working memory performance, providing a mechanistic explanation for cognitive changes previously associated with dysbindin expression. CONCLUSIONS: These data show a significant downregulation of NMDA receptors due to dysbindin deficiency and illuminate molecular mechanisms mediating the association between dysbindin insufficiency and cognitive impairments associated with schizophrenia, encouraging study of the dysbindin/NR1 expression association in humans with schizophrenia.
BACKGROUND:Schizophrenia is a heritable disorder associated with disrupted neural transmission and dysfunction of brain systems involved in higher cognition. The gene encoding dystrobrevin-binding-protein-1 (dysbindin) is a putative candidate gene associated with cognitive impairments, including memory deficits, in both schizophreniapatients and unaffected individuals. The underlying mechanism is thought to be based in changes in glutamatergic and dopaminergic function within the corticostriatal networks known to be critical for schizophrenia. This hypothesis derives support from studies of mice with a null mutation in the dysbindin gene that exhibit memory dysfunction and excitatory neurotransmission abnormalities in prefrontal and hippocampal networks. At a cellular level, dysbindin is thought to mediate presynaptic glutamatergic transmission. METHODS: We investigated the relationship between glutamate receptor dynamics and memory performance in dysbindin mutant mice. We assessed N-methyl-D-aspartate (NMDA) and α-amino-3-hydroxy-5-methylisoxazole-4-propionic acid receptor function in prefrontal cortex pyramidal neurons in vitro with whole-cell recordings, molecular quantitative analyses (reverse transcription-polymerase chain reaction) of the mandatory NMDA receptor subunit NR1, and cognitive function with a spatial working memory task. RESULTS: Decreases in dysbindin are associated with specific decreases in NMDA-evoked currents in prefrontal pyramidal neurons, as well as decreases in NR1 expression. Furthermore, the degree of NR1 expression correlates with spatial working memory performance, providing a mechanistic explanation for cognitive changes previously associated with dysbindin expression. CONCLUSIONS: These data show a significant downregulation of NMDA receptors due to dysbindindeficiency and illuminate molecular mechanisms mediating the association between dysbindininsufficiency and cognitive impairments associated with schizophrenia, encouraging study of the dysbindin/NR1 expression association in humans with schizophrenia.
Authors: R E Straub; C J MacLean; Y Ma; B T Webb; M V Myakishev; C Harris-Kerr; B Wormley; H Sadek; B Kadambi; F A O'Neill; D Walsh; K S Kendler Journal: Mol Psychiatry Date: 2002 Impact factor: 15.992
Authors: Danielle Posthuma; Michelle Luciano; Eco J C de Geus; Margie J Wright; P Eline Slagboom; Grant W Montgomery; Dorret I Boomsma; Nicholas G Martin Journal: Am J Hum Genet Date: 2005-07-01 Impact factor: 11.025
Authors: T D Cannon; M O Huttunen; J Lonnqvist; A Tuulio-Henriksson; T Pirkola; D Glahn; J Finkelstein; M Hietanen; J Kaprio; M Koskenvuo Journal: Am J Hum Genet Date: 2000-07-03 Impact factor: 11.025
Authors: Konrad Talbot; Wess L Eidem; Caroline L Tinsley; Matthew A Benson; Edward W Thompson; Rachel J Smith; Chang-Gyu Hahn; Steven J Siegel; John Q Trojanowski; Raquel E Gur; Derek J Blake; Steven E Arnold Journal: J Clin Invest Date: 2004-05 Impact factor: 14.808
Authors: George Kirov; Dobril Ivanov; Nigel M Williams; Anna Preece; Ivan Nikolov; Radoi Milev; Svetlinka Koleva; Albena Dimitrova; Draga Toncheva; Michael C O'Donovan; Michael J Owen Journal: Biol Psychiatry Date: 2004-05-15 Impact factor: 13.382
Authors: Yong Chen; Sookhee Bang; Mary F McMullen; Hala Kazi; Konrad Talbot; Mei-Xuan Ho; Greg Carlson; Steven E Arnold; Wei-Yi Ong; Sangwon F Kim Journal: Mol Neurobiol Date: 2016-02-12 Impact factor: 5.590
Authors: Avanti Gokhale; Cortnie Hartwig; Amanda H Freeman; Ravi Das; Stephanie A Zlatic; Rachel Vistein; Amelia Burch; Guillemette Carrot; Arielle F Lewis; Sheldon Nelms; Dion K Dickman; Manojkumar A Puthenveedu; Daniel N Cox; Victor Faundez Journal: J Neurosci Date: 2016-12-07 Impact factor: 6.167
Authors: Glenn T Konopaske; Darrick T Balu; Kendall T Presti; Grace Chan; Francine M Benes; Joseph T Coyle Journal: Schizophr Res Date: 2018-05-11 Impact factor: 4.939
Authors: Sandra M Holley; Elizabeth A Wang; Carlos Cepeda; J David Jentsch; Christopher A Ross; Mikhail V Pletnikov; Michael S Levine Journal: Schizophr Res Date: 2013-03-06 Impact factor: 4.939